Madrigal Pharma (MDGL): FDA Approves rezdiffra
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
(Updated - March 14, 2024 3:52 PM EDT)
Madrigal Pharma (NASDAQ: MDGL): FDA Approves rezdiffra - website.
- Rezdiffra indicated in conjunction with diet, exercise for treatment of adults with NASH with moderate to advanced liver fibrosis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves AbbVie's Skyrizi for children with plaque psoriasis
- INmune Bio gets MHRA alignment for 2026 UK drug application
- Amylyx ALS drug shows no serious adverse events in Phase 1 trial
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
